

# Karen Anderson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8824343/publications.pdf>

Version: 2024-02-01

96  
papers

4,022  
citations

126907

33  
h-index

128289

60  
g-index

132  
all docs

132  
docs citations

132  
times ranked

4171  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanism and fidelity of HIV reverse transcriptase.. Journal of Biological Chemistry, 1992, 267, 25988-25997.	3.4	446
2	Mechanism and fidelity of HIV reverse transcriptase. Journal of Biological Chemistry, 1992, 267, 25988-97.	3.4	375
3	Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations. ACS Central Science, 2021, 7, 467-475.	11.3	182
4	Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2. ACS Medicinal Chemistry Letters, 2020, 11, 2526-2533.	2.8	176
5	Current Perspectives on HIV-1 Antiretroviral Drug Resistance. Viruses, 2014, 6, 4095-4139.	3.3	129
6	Computationally-Guided Optimization of a Docking Hit to Yield Catechol Diethers as Potent Anti-HIV Agents. Journal of Medicinal Chemistry, 2011, 54, 8582-8591.	6.4	122
7	Insights into the Molecular Mechanism of Mitochondrial Toxicity by AIDS Drugs. Journal of Biological Chemistry, 2001, 276, 23832-23837.	3.4	119
8	Serine modulates substrate channeling in tryptophan synthase. A novel intersubunit triggering mechanism. Journal of Biological Chemistry, 1991, 266, 8020-33.	3.4	114
9	Data publication with the structural biology data grid supports live analysis. Nature Communications, 2016, 7, 10882.	12.8	113
10	Intracellular transport of class I MHC molecules in antigen processing mutant cell lines. Journal of Immunology, 1993, 151, 3407-19.	0.8	83
11	APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene, 2019, 38, 3475-3487.	5.9	81
12	Mechanistic Studies Comparing the Incorporation of (+) and (̂) Isomers of 3TCTP by HIV-1 Reverse Transcriptase. Biochemistry, 1999, 38, 55-63.	2.5	78
13	Picomolar Inhibitors of HIV Reverse Transcriptase Featuring Bicyclic Replacement of a Cyanovinylphenyl Group. Journal of the American Chemical Society, 2013, 135, 16705-16713.	13.7	78
14	HIV-1 Reverse Transcriptase Resistance to Nonnucleoside Inhibitors. Biochemistry, 1996, 35, 1054-1063.	2.5	75
15	Relationship between Antiviral Activity and Host Toxicity: Comparison of the Incorporation Efficiencies of 2,3-Dideoxy-5-Fluoro-3-Thiacytidine-Triphosphate Analogs by Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Human Mitochondrial DNA Polymerase. Antimicrobial Agents and Chemotherapy, 2004, 48, 1300-1306.	3.2	71
16	Mechanistic studies show that (̂)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB Journal, 1999, 13, 1511-1517.	0.5	66
17	RNA Dependent DNA Replication Fidelity of HIV-1 Reverse Transcriptase: Evidence of Discrimination between DNA and RNA Substrates. Biochemistry, 1997, 36, 14056-14063.	2.5	65
18	Efficient Discovery of Potent Anti-HIV Agents Targeting the Tyr181Cys Variant of HIV Reverse Transcriptase. Journal of the American Chemical Society, 2011, 133, 15686-15696.	13.7	64

#	ARTICLE	IF	CITATIONS
19	Substrate Channeling and Domain-Domain Interactions in Bifunctional Thymidylate Synthase-Dihydrofolate Reductase. <i>Biochemistry</i> , 1998, 37, 12195-12205.	2.5	60
20	Illuminating the Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance for the FGFR1 Gatekeeper Mutation: The Achilles' Heel of Targeted Therapy. <i>ACS Chemical Biology</i> , 2015, 10, 1319-1329.	3.4	57
21	Crystal Structures of HIV-1 Reverse Transcriptase with Picomolar Inhibitors Reveal Key Interactions for Drug Design. <i>Journal of the American Chemical Society</i> , 2012, 134, 19501-19503.	13.7	48
22	Structure-Based Evaluation of Non-nucleoside Inhibitors with Improved Potency and Solubility That Target HIV Reverse Transcriptase Variants. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2737-2745.	6.4	48
23	Crystallographic Studies of Phosphonate-Based $\ddagger$ -Reaction Transition-State Analogues Complexed to Tryptophan Synthase. <i>Biochemistry</i> , 1999, 38, 12665-12674.	2.5	47
24	Surface point mutations that significantly alter the structure and stability of a protein's denatured state. <i>Protein Science</i> , 1996, 5, 2009-2019.	7.6	46
25	Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 9725-9730.	7.1	43
26	Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease. <i>Structure</i> , 2021, 29, 823-833.e5.	3.3	43
27	Intersubunit Communication in Tryptophan Synthase by Carbon-13 and Fluorine-19 REDOR NMR. <i>Biochemistry</i> , 1996, 35, 3328-3334.	2.5	42
28	A role for calnexin (IP90) in the assembly of class II MHC molecules. <i>EMBO Journal</i> , 1994, 13, 675-82.	7.8	42
29	Mechanism of Inhibition of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase by d4TTP: an Equivalent Incorporation Efficiency Relative to the Natural Substrate dTTP. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 217-221.	3.2	39
30	Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1259-1262.	2.8	39
31	Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase $\beta$ . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8596-8601.	7.1	37
32	Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1325-1332.	2.8	37
33	The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT. <i>Molecular Cancer Research</i> , 2019, 17, 532-543.	3.4	35
34	Extension into the entrance channel of HIV-1 reverse transcriptase-Crystallography and enhanced solubility. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5209-5212.	2.2	33
35	First Three-Dimensional Structure of <i>Toxoplasma gondii</i> Thymidylate Synthase-Dihydrofolate Reductase: Insights for Catalysis, Interdomain Interactions, and Substrate Channeling. <i>Biochemistry</i> , 2013, 52, 7305-7317.	2.5	32
36	Kinetic Characterization of Bifunctional Thymidylate Synthase-Dihydrofolate Reductase (TS-DHFR) from <i>Cryptosporidium hominis</i> . <i>Journal of Biological Chemistry</i> , 2004, 279, 18314-18322.	3.4	30

#	ARTICLE	IF	CITATIONS
37	From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E802-E811.	7.1	30
38	Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2002, 1587, 296-299.	3.8	29
39	Structural studies provide clues for analog design of specific inhibitors of <i>Cryptosporidium hominis</i> thymidylate synthase–dihydrofolate reductase. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4158-4161.	2.2	28
40	Activity and fidelity of human DNA polymerase $\beta$ depend on primer structure. Journal of Biological Chemistry, 2018, 293, 6824-6843.	3.4	28
41	Insights into DNA substrate selection by APOBEC3G from structural, biochemical, and functional studies. PLoS ONE, 2018, 13, e0195048.	2.5	25
42	Interactions of enantiomers of 2 $\beta$ ,3 $\beta$ -didehydro-2 $\beta$ ,3 $\beta$ -dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. Antiviral Research, 2002, 56, 189-205.	4.1	24
43	Insights into the Molecular Mechanism of Polymerization and Nucleoside Reverse Transcriptase Inhibitor Incorporation by Human PrimPol. Antimicrobial Agents and Chemotherapy, 2016, 60, 561-569.	3.2	24
44	Discovery of Potent and Selective Inhibitors of <i>Toxoplasma gondii</i> Thymidylate Synthase for Opportunistic Infections. ACS Medicinal Chemistry Letters, 2013, 4, 1148-1151.	2.8	23
45	Fluorescence Resonance Energy Transfer Studies of DNA Polymerase $\beta$ . Journal of Biological Chemistry, 2014, 289, 16541-16550.	3.4	23
46	Implication of the tRNA Initiation Step for Human Immunodeficiency Virus Type 1 Reverse Transcriptase in the Mechanism of 3 $\beta$ -Azido-3 $\beta$ -deoxythymidine (AZT) Resistance. Biochemistry, 1998, 37, 14189-14194.	2.5	22
47	Probing the Mechanistic Consequences of 5-Fluorine Substitution on Cytidine Nucleotide Analogue Incorporation by HIV-1 Reverse Transcriptase. Antiviral Chemistry and Chemotherapy, 2003, 14, 115-125.	0.6	22
48	Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance. ACS Medicinal Chemistry Letters, 2015, 6, 1075-1079.	2.8	22
49	Design, Conformation, and Crystallography of 2-Naphthyl Phenyl Ethers as Potent Anti-HIV Agents. ACS Medicinal Chemistry Letters, 2016, 7, 1156-1160.	2.8	22
50	MYB fusions and CD markers as tools for authentication and purification of cancer stem cells from salivary adenoid cystic carcinoma. Stem Cell Research, 2017, 21, 160-166.	0.7	22
51	Substituted pyrrolo[2,3-d]pyrimidines as <i>Cryptosporidium hominis</i> thymidylate synthase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5426-5428.	2.2	21
52	Structure-Based Evaluation of C5 Derivatives in the Catechol Diether Series Targeting HIV-1 Reverse Transcriptase. Chemical Biology and Drug Design, 2014, 83, 541-549.	3.2	21
53	Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine. Protein Science, 2019, 28, 1664-1675.	7.6	20
54	The Catalytic Mechanism of EPSP Synthase Revisited. Biochemistry, 1999, 38, 7372-7379.	2.5	19

#	ARTICLE	IF	CITATIONS
55	Illuminating HIV gp120-ligand recognition through computationally-driven optimization of antibody-recruiting molecules. <i>Chemical Science</i> , 2014, 5, 2311-2317.	7.4	19
56	Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4824-4827.	2.2	19
57	Novel non-active site inhibitor of <i>Cryptosporidium hominis</i> TS-DHFR identified by a virtual screen. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 418-423.	2.2	18
58	Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors. <i>Molecular Cancer Research</i> , 2015, 13, 765-774.	3.4	17
59	Exploring novel strategies for AIDS protozoal pathogens: $\beta$ -helix mimetics targeting a key allosteric protein-protein interaction in <i>C. hominis</i> thymidylate synthase-dihydrofolate reductase (TS-DHFR). <i>MedChemComm</i> , 2013, 4, 1247-1256.	3.4	16
60	Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4-ethynyl-2-fluoro-2-deoxyadenosine (EFdA) using pre-steady-state kinetics. <i>Antiviral Research</i> , 2014, 106, 1-4.	4.1	16
61	Identifying the role of PrimPol in TDF-induced toxicity and implications of its loss of function mutation in an HIV+ patient. <i>Scientific Reports</i> , 2020, 10, 9343.	3.3	16
62	Nonconserved Residues Ala287 and Ser290 of the <i>Cryptosporidium hominis</i> Thymidylate Synthase Domain Facilitate Its Rapid Rate of Catalysis. <i>Biochemistry</i> , 2007, 46, 8379-8391.	2.5	15
63	Understanding the molecular mechanism of substrate channeling and domain communication in protozoal bifunctional TS-DHFR. <i>Protein Engineering, Design and Selection</i> , 2017, 30, 255-264.	2.1	15
64	Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV. <i>Antiviral Research</i> , 2019, 167, 110-116.	4.1	15
65	Structure-Guided Identification of DNMT3B Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 971-976.	2.8	15
66	Covalent Inhibition of Wild-Type HIV-1 Reverse Transcriptase Using a Fluorosulfate Warhead. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 249-255.	2.8	15
67	Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection. <i>Molecular Pharmacology</i> , 2017, 91, 383-391.	2.3	14
68	Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. <i>FASEB Journal</i> , 2001, 15, 1902-1908.	0.5	13
69	An allosteric site on MKP5 reveals a strategy for small-molecule inhibition. <i>Science Signaling</i> , 2020, 13, eaba3043.	3.6	12
70	MECHANISTIC STUDIES TO UNDERSTAND THE INHIBITION OF WILD TYPE AND MUTANT HIV-1 REVERSE TRANSCRIPTASE BY CARBOVIR-TRIPHOSPHATE. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2001, 20, 1247-1250.	1.1	11
71	A nanotherapy strategy significantly enhances anticryptosporidial activity of an inhibitor of bifunctional thymidylate synthase-dihydrofolate reductase from <i>Cryptosporidium</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2065-2067.	2.2	11
72	Platination of cysteine by an epidermal growth factor receptor kinase-targeted hybrid agent. <i>Chemical Communications</i> , 2018, 54, 7479-7482.	4.1	11

#	ARTICLE	IF	CITATIONS
73	Detection of novel enzyme intermediates in PEP-utilizing enzymes. Archives of Biochemistry and Biophysics, 2005, 433, 47-58.	3.0	10
74	A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 2203-2211.	2.4	10
75	Explaining an Unusually Fast Parasitic Enzyme: Folate Tail-Binding Residues Dictate Substrate Positioning and Catalysis in <i>Cryptosporidium hominis</i> Thymidylate Synthase. Biochemistry, 2008, 47, 8902-8911.	2.5	9
76	Virtual screening reveals allosteric inhibitors of the <i>Toxoplasma gondii</i> thymidylate synthase dihydrofolate reductase. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1232-1235.	2.2	9
77	Design, Synthesis, and Antiviral Evaluation of Chimeric Inhibitors of HIV Reverse Transcriptase. ACS Medicinal Chemistry Letters, 2013, 4, 1183-1188.	2.8	8
78	The DNA Polymerase Gamma R953C Mutant Is Associated with Antiretroviral Therapy-Induced Mitochondrial Toxicity. Antimicrobial Agents and Chemotherapy, 2016, 60, 5608-5611.	3.2	8
79	Structural investigation of naphthyl phenyl ether inhibitors bound to WT and Y181C reverse transcriptase highlights key features of the NNRTI binding site. Protein Science, 2020, 29, 1902-1910.	7.6	7
80	Global Genome Demethylation Causes Transcription-Associated DNA Double Strand Breaks in HPV-Associated Head and Neck Cancer Cells. Cancers, 2021, 13, 21.	3.7	7
81	Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase. Frontiers in Molecular Biosciences, 2022, 9, 805187.	3.5	7
82	A transient kinetic approach to investigate nucleoside inhibitors of mitochondrial DNA polymerase $\beta$ . Methods, 2010, 51, 392-398.	3.8	6
83	DRONE: Direct Tracking of DNA Cytidine Deamination and Other DNA Modifying Activities. Analytical Chemistry, 2018, 90, 11735-11740.	6.5	6
84	Novel allosteric covalent inhibitors of bifunctional <i>Cryptosporidium hominis</i> TS-DHFR from parasitic protozoa identified by virtual screening. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1413-1418.	2.2	6
85	Structure activity relationship towards design of cryptosporidium specific thymidylate synthase inhibitors. European Journal of Medicinal Chemistry, 2019, 183, 111673.	5.5	5
86	Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2182-2188.	2.2	4
87	Platelet-derived growth factor receptor beta activates Abl2 via direct binding and phosphorylation. Journal of Biological Chemistry, 2021, 297, 100883.	3.4	4
88	Understanding the structural basis of species selective, stereospecific inhibition for <i>Cryptosporidium</i> and human thymidylate synthase. FEBS Letters, 2019, 593, 2069-2078.	2.8	3
89	Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance. Molecules, 2020, 25, 4868.	3.8	3
90	Targeting the TS dimer interface in bifunctional <i>Cryptosporidium hominis</i> TS-DHFR from parasitic protozoa: Virtual screening identifies novel TS allosteric inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127292.	2.2	2

#	ARTICLE	IF	CITATIONS
91	The molecular basis of inhibition and toxicity of modified cytosine analogues targetting HIV-1 reverse transcriptase. <i>Antiviral Chemistry and Chemotherapy</i> , 2001, 12 Suppl 1, 13-7.	0.6	2
92	Crystallization and preliminary X-ray investigation of the recombinant <i>Trypanosoma brucei</i> rhodesiense calmodulin. <i>Proteins: Structure, Function and Bioinformatics</i> , 1995, 21, 354-357.	2.6	1
93	Yale Cancer Center Precision Medicine Tumor Board: one tumour, multiple targets. <i>Lancet Oncology</i> , The, 2018, 19, 1567-1568.	10.7	1
94	Reply to Pandey et al.: Understanding the efficacy of a potential antiretroviral drug candidate in humanized mouse model of HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8114-E8115.	7.1	0
95	Biochemical and Functional Characterization of the Mutagenic Cytidine Deaminase, APOBEC3B. <i>FASEB Journal</i> , 2015, 29, 573.48.	0.5	0
96	Human PrimPol: A Novel Mechanism of Antiviral Toxicity. <i>FASEB Journal</i> , 2015, 29, 710.23.	0.5	0